Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

View:
Post by DeadPool007 on Aug 04, 2020 7:50pm

Funding

If you recall the pictures on twitter from two months ago, Michael stated they had enough funds to start the study. They also have Pharm Olam that can help with the grants application. https://twitter.com/havin_nadarajah/status/1271450181645537281?s=19
Comment by mrnormal on Aug 04, 2020 8:21pm
Yuppers, that's been an ace up our sleeve for sure.  I think Michael went on radio silence after that was shared. For good reason. He's a pretty tight lipped guy.    
Comment by 90guppy on Aug 04, 2020 8:53pm
RVV has enough money to finish the trials. In the Management Discussion Analysis submitted on May 29th, on page 14, you will see the amount that they will need to finish the trials. According to the MD&A, they will need only $200k to finish it. https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00034460&issuerType=03&projectNo=03066479&docId=4736154
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse